ScripsAmerica’s Specialty Pharmacy Records Over $5 Million in Approved Orders for the Third Consecutive Month


TYSONS CORNER, VA–(Marketwired – Dec 3, 2014) - ScripsAmerica, Inc. (OTCBB: SCRC) today announced that its wholly owned subsidiary, Main Avenue Pharmacy, reported $5,257,753 in approved orders during November of 2014. This represents the third consecutive month that ScripsAmerica’s specialty pharmacy generated over $5 million in sales.

CEO of ScripsAmerica, Bob Schneiderman, commented, “We are pleased that our specialty pharmacy continues to report tremendous revenues and is maintaining an annual run rate over $60 million. As ScripsAmerica closes 2014 in a very strong financial position where revenues have experienced dramatic growth, we are currently profitable and have a favorable capital structure with less than 138 million shares outstanding, we believe the company is greatly undervalued right now.”

“Management is highly committed to maximizing Scrips’ exposure in the investment community in order to propel the Company toward an accurate valuation which would increase shareholder value significantly,” added Schneiderman.

About ScripsAmerica, Inc.

ScripsAmerica, Inc. is a supplier of prescription, OTC and nutraceutical drugs, delivering pharmaceutical products to a wide range of end users across the health care industry. End users include retail pharmacies, hospitals, long-term care facilities and government and home care agencies. For more information, visit www.ScripsAmerica.com.

Safe Harbor Statement

This release includes forward-looking statements, which are based on certain assumptions and reflects management’s current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

CONTACT INFORMATION

  •  

    Contact: 

    Seal Point Consulting, LLC
    888-959-7095
    Email Contact

About author

This article was written by The Wall Street Analyzer

The Wall Street Analyzer's staff of writers, analysts, publishers, producers, market researchers, and PR professionals aim to provide investors with the tools they need to make informed decisions on buying stock. Our staff is a mix of financial professionals and media savvy individuals whose experiences bring the best talent from both ends of the spectrum. On one hand our financial experience gives us the ability to identify promising, off the grid companies before they are uncovered by the rest of the market, and on the other hand our media experience allows us to produce interviews which appeal to a large audience because we provide a format in which more investors can understand a featured companies' upside. Our philosophy is to turn stock tickers into stories, ideas into headlines, and technical and financial data into easy to understand tidbits, easier to digest and therefore consumed by a larger audience. These interviews provide a jumping off point for investors to do further research into a prospective company. Our editorials seek to provide an out-of-the-box perspective found in few other financial sites.